A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data
Cephalalgia · 2025
DOI: 10.1177/03331024251352849 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cephalalgia, 2025. Verfasst von Stewart J Tepper und 6 weiteren Autor:innen. Beteiligte Einrichtung: The New England Institute for Neurology and Headache, Stamford, Connecticut, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Tryptamines, Piperidines, Pyridines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer UK.
Abstract (Originalsprache)
Background
This study compared persistence of patients initiating rimegepant versus oral triptans for the acute treatment of migraine.
Methods
A retrospective cohort analysis was conducted using US MarketScan claims data (1 March 2019 to 30 June 2023) among commercially- and US federal Medicare-insured migraine patients initiating rimegepant or oral triptans. Persistence was defined as having ≥1 refill within 12 months of initial prescription and was compared between propensity score-matched rimegepant and triptan cohorts.
Results
Before matching, 13,599 patients were identified in the rimegepant cohort and 38,127 in the triptan cohort. After matching, each cohort included 9909 patients. Significantly more rimegepant patients were persistent (75.8%) versus triptan patients (53.5%) (odds ratio [OR] 2.72, 95% confidence interval [CI] 2.56–2.90). Subgroup analyses showed similar trends for rimegepant versus specific triptans (rizatriptan: OR 2.49 [95% CI 2.33–2.67], and sumatriptan: OR 2.92 [95% CI 2.73–3.12]) and in patients with chronic migraine (OR 2.86 [95% CI 2.53–3.23]).
Conclusions
This study provides compelling evidence that rimegepant is associated with greater persistence than oral triptans for real-world acute treatment of migraine. Rimegepant is a favorable option for patients seeking effective and tolerable long-term treatment, particularly for those with insufficient response, intolerability, or contraindications to triptans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The New England Institute for Neurology and Headache, Stamford, Connecticut, USA.
- Pfizer R&D UK Ltd, Tadworth, Surrey, UK.
- Henriksen Analytic Insights, LLC, Gainesville, FL, USA.
- Pfizer Inc, New York, NY, USA.
- Pfizer Ltd, Tadworth, Surrey, UK.
- Praxis Gendolla, Essen, Germany.
ORCID-Profile: Stewart J Tepper, Aaron Jenkins, Carl Henriksen, Feng Dai, Jo Atkinson, Lucy Abraham
Förderung
- Pfizer UK
Zitieren
APA
Tepper, S. J., Jenkins, A., Henriksen, C., Dai, F., Atkinson, J., Abraham, L., & Gendolla, A. (2025). A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data. Cephalalgia. https://doi.org/10.1177/03331024251352849
Vancouver
Tepper SJ, Jenkins A, Henriksen C, Dai F, Atkinson J, Abraham L, et al. A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data. Cephalalgia. 2025. doi:10.1177/03331024251352849
BibTeX
@article{Tepper2025,
author = {Tepper, Stewart J and Jenkins, Aaron and Henriksen, Carl and Dai, Feng and Atkinson, Jo and Abraham, Lucy and Gendolla, Astrid},
title = {A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251352849}
}
EUVIMED